Every 8-K that Kura Oncology, Inc. (KURA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KURA filings page.
Kura Oncology, Inc. (symbol: KURA) is the issuer of record for a Form 8-K filing submitted to the SEC.
Kura Oncology, Inc. (KURA) appointed Jennifer Fulk as Chief Financial Officer, principal financial officer and principal accounting officer effective September 8, 2026, replacing Troy E. Wilson, Ph.D., J.D. and Thomas Doyle in those specific roles. Fulk brings prior CFO and operating experience at Soleno Therapeutics, 120Water, Talkspace and Eli Lilly and Company.
Under her September 8, 2026 employment agreement, Fulk receives a $550,000 annual base salary, is eligible for an annual discretionary bonus of up to 45% of base salary, an option to purchase 450,000 shares of common stock and a one-time performance-based restricted stock unit award covering 173,438 shares. The option vests over four years and the PSUs vest in six installments based on revenue, clinical and regulatory milestones.
The agreement provides cash severance, COBRA premium payments, option exercise extensions and, in a qualifying termination in connection with a Corporate Transaction, additional cash, extended COBRA coverage and full acceleration of all outstanding equity awards, with performance-based awards vesting at target.
Kura Oncology reported second quarter 2026 results, highlighting early commercial traction for KOMZIFTI (ziftomenib) in relapsed or refractory NPM1-mutated AML. Net product revenue was $9.1 million, with approximately 115 new patient starts and more than 250 total prescriptions, all growing strongly versus the prior quarter, and KOMZIFTI achieved a majority share of new patient starts in its menin inhibitor class.
Total revenue was $20.9 million, including $11.8 million of collaboration revenue. Kura recorded a net loss of $68.3 million, with R&D expense of $61.9 million and SG&A of $31.8 million. Cash, cash equivalents and short-term investments were $519.0 million as of June 30, 2026, and together with $180 million in anticipated collaboration payments, management expects funding to support the ziftomenib AML program through topline Phase 3 KOMET-017 results anticipated in 2028.
Clinical updates showed high and durable responses for ziftomenib combinations in frontline and relapsed AML, and encouraging activity for darlifarnib combinations across KRAS-mutated tumors and clear cell renal cell carcinoma, supporting its positioning as a precision combination platform and multiple ongoing and planned studies.
Kura Oncology amended and restated executive employment agreements for its Chairman, President and CEO Troy E. Wilson, Chief Commercial Officer Brian Powl and Chief Operating Officer Kathleen Ford to modify severance protections, including change‑of‑control terms tied to a Corporate Transaction.
If Wilson is terminated without Cause or resigns for Good Reason outside the Corporate Transaction window, he receives a lump sum equal to 12 months base salary, up to 12 months COBRA premiums and a 12‑month stock option exercise period. If the separation occurs within 59 days before, on, or within 18 months after a Corporate Transaction, his cash severance increases to 24 months salary plus 200% of target bonus, with up to 24 months COBRA, full equity vesting at target and a 12‑month option exercise period. Powl and Ford receive similar protections, with 12 months salary outside a Corporate Transaction and, within the transaction window, 18 months salary, 150% of target bonus, extended COBRA, full equity vesting and a 12‑month option exercise period.
Kura Oncology, Inc. reported results of its Annual Meeting of Stockholders and approval of expanded equity compensation plans. Stockholders approved amendments to the 2014 Equity Incentive Plan adding 6,500,000 shares and to the 2015 Employee Stock Purchase Plan adding 2,500,000 shares for future awards.
As of the April 6, 2026 record date, 88,762,704 shares of common stock were outstanding, and 69,778,580 shares were present or represented by proxy. Stockholders elected three Class III directors to terms ending at the 2029 annual meeting, ratified Ernst & Young LLP as auditor, approved executive compensation on an advisory basis, chose an annual say‑on‑pay vote, and confirmed both the amended equity plan and ESPP.
Kura Oncology reported first quarter 2026 results highlighted by the first commercial sales of KOMZIFTI, its menin inhibitor for relapsed or refractory NPM1‑mutated AML. KOMZIFTI generated $5.8 million in net product revenue, with 85 new patient starts, 157 total prescriptions and more than 93% payer coverage.
Total revenue was $18.3 million, up from $14.1 million a year earlier, driven by new product revenue and $12.5 million of collaboration revenue. Kura posted a net loss of $73.3 million as it increased R&D and commercialization spending. Cash and investments of $580.8 million, plus $180 million in anticipated collaboration payments, are expected to fund its ziftomenib AML program through topline Phase 3 KOMET‑017 results anticipated in 2028.
Kura Oncology reported its first commercial revenue from KOMZIFTI (ziftomenib) alongside fourth quarter and full year 2025 results. KOMZIFTI, the first approved once-daily oral menin inhibitor for relapsed or refractory NPM1‑mutated AML, generated $2.1 million in net product revenue in Q4 2025 from about five weeks of sales.
Total Q4 2025 revenue was $17.3 million, driven by $15.2 million of collaboration revenue, down from $53.9 million a year earlier. Higher investment in development and commercialization increased R&D expenses to $64.4 million and SG&A to $39.1 million, resulting in a Q4 net loss of $81.0 million, compared with a $19.2 million loss in Q4 2024.
For full year 2025, net loss was $278.7 million. The company ended 2025 with $667.2 million in cash, cash equivalents and short-term investments and expects this, together with $180 million in anticipated collaboration payments, to fund its ziftomenib AML program through first topline Phase 3 KOMET‑017 frontline results, anticipated in 2028, and to support its broader pipeline into the fourth quarter of 2027.
Kura Oncology, Inc. has adopted amended and restated bylaws that significantly update its corporate governance rules for stockholder meetings, director nominations and board procedures. The changes refine who can call, postpone or adjourn meetings, adjust quorum and voting standards, and align notice provisions with Delaware law.
The bylaws tighten advance notice and disclosure requirements for stockholder proposals and director nominations, limit substitute nominees, and require proponents to provide detailed information and certifications. They also expand indemnification and expense advancement for directors and officers to the maximum extent allowed by law and enhance forum selection provisions, including a federal forum clause for Securities Act claims.
Kura Oncology, Inc. filed a current report to furnish a press release dated January 11, 2026. The press release highlights the company’s recent accomplishments, reports preliminary revenue for its product KOMZIFTI™ (ziftomenib), and outlines anticipated milestones for 2026. The press release is attached as Exhibit 99.1. The information provided under Item 2.02 and in Exhibit 99.1 is being furnished, not filed, which means it is not subject to certain liability provisions of the Securities Exchange Act and will only be incorporated into future Securities Act registration statements if specifically identified.
Kura Oncology (KURA) announced that the FDA granted full approval of KOMZIFTI (ziftomenib) for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. KOMZIFTI is the first and only once-daily, oral menin inhibitor approved for this R/R NPM1‑mutated AML population.
Approval is supported by the pivotal KOMET‑001 trial in 112 patients, showing a complete remission (CR) plus CR with partial hematologic recovery (CRh) rate of 21.4% (95% CI: 14.2, 30.2). Median duration of CR+CRh was 5.0 months (95% CI: 1.9, 8.1), and median time to first response among responders was 2.7 months, with 88% achieving CR or CRh within six months of starting therapy. The label includes a Boxed Warning for differentiation syndrome, and common adverse reactions (≥20%) included liver enzyme elevations, infections, electrolyte changes, hemorrhage, gastrointestinal events, fatigue, edema, and QTc interval prolongation (≤ Grade 3 in 12% of patients; no Grade 4/5 reported). The wholesale acquisition cost for a one‑month supply is $48,500. Kura leads U.S. development, regulatory and commercial strategy and manufacturing under its collaboration with Kyowa Kirin; Kyowa Kirin leads outside the United States.
Kura Oncology (KURA) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025, along with a corporate update.
The information under Item 2.02 and Exhibit 99.1 is being furnished, not deemed “filed” under Section 18 of the Exchange Act, and will not be incorporated by reference into Securities Act registrations unless specifically identified.
Kura Oncology announced receipt of a $30 million milestone payment from Kyowa Kirin. The payment was triggered by dosing the first patient in KOMET-017, a pair of Phase 3 registrational trials evaluating ziftomenib, a once-daily, investigational oral menin inhibitor.
KOMET-017 consists of two independent, global, randomized double-blind, placebo-controlled Phase 3 studies. They assess ziftomenib in combination with intensive and non‑intensive chemotherapy in adults with newly diagnosed NPM1‑mutated or KMT2A‑rearranged acute myeloid leukemia. The payment provides non-dilutive funding aligned with the advancement of ziftomenib into late‑stage testing.
Kura Oncology amended its 2023 Inducement Option Plan to reserve an additional 750,000 shares of common stock, increasing the plan’s total reserve to 3,250,000 shares. These shares are designated exclusively for nonstatutory stock option grants to new hires as an inducement to join the company, consistent with Nasdaq Listing Rule 5635(c)(4). The Board approved the amendment on October 15, 2025, without stockholder approval as permitted by the rule. A complete copy of the amended plan is filed as Exhibit 99.1.
Kura Oncology (KURA) filed an 8-K announcing updated Phase 1a/1b results for ziftomenib, its oral menin inhibitor, from the KOMET-007 study in newly diagnosed AML patients with NPM1-m or KMT2A-r mutations. The 600 mg QD dose given with standard 7+3 chemotherapy produced robust composite complete remission (CRc) of 92 % (65/71) and complete remission (CR) of 80 % (57/71), with similar efficacy across both genetic sub-groups (CRc: 93 % NPM1-m, 89 % KMT2A-r). MRD-negative CR rates reached 71 % for NPM1-m and 88 % for KMT2A-r, achieved in roughly 4–5 weeks.
Durability signals are emerging: median CR duration and overall survival have not yet been reached in NPM1-m patients after a median 24.9-week follow-up; KMT2A-r patients show a median CR duration of 25.6 weeks with OS not reached. Survival remains high, with 96 % (NPM1-m) and 88 % (KMT2A-r) alive and on study.
The pooled safety set (n = 82) showed a profile consistent with prior data. ≥Grade 3 treatment-related adverse events >10 % included febrile neutropenia (15 %), thrombocytopenia (15 %), anemia (11 %) and neutropenia (11 %). Importantly, there were no dose-limiting toxicities, meaningful QTc prolongation, drug–drug interactions or additive myelosuppression; a single grade-3 differentiation syndrome case was successfully managed.
Kura plans to initiate the KOMET-017 randomized Phase 3 trials (intensive and non-intensive chemo backbones) in 2H 2025. The company also hosted a virtual investor event on 18 Jun 2025 (Exhibit 99.1) to discuss the data.